Evaluated by: David B. Kaminsky, M.D., FIAC, July 8, 2018
Original release date: October 3, 2018
Access to this course expires on: July 8, 2021, at 11:59 PM (PT)
CME 29.25 | SAM 23.75
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
- Explain the value and limitations of genetic testing in SBCL
- Discuss the testing modalities and differential diagnosis of SBCL
- Recognize the histologic features of gastroesophageal diseases
- Distinguish inflammatory bowel disease from other types of colitis
- Distinguish idiopathic inflammatory bowel disease from other types of chronic injury
- Distinguish adenosis, partial atrophy, and nonspecific granulomatous prostatitis from prostate cancer
- Recognize how to use basal cell markers and AMACR in the diagnosis of limited prostate cancer on biopsy
- Recognize the microscopic features of key HPV-positive head and neck cancers
- Interpret key tests for HPV-positive oropharyngeal carcinomas
- Recognize novel immunohistochemical markers for spindle cell tumors of soft tissue
- Apply immunohistochemistry to aid in the differential diagnosis of spindle cell tumors of soft tissue
- Discuss the morphological spectrum and differential diagnosis of the various types of ovarian sex cord-stromal tumour
- Explain the dualistic pathway of low-grade and high-grade serous carcinoma
- Identify which immunohistochemical markers are useful in the diagnosis of ovarian sex cord-stromal tumours
- Recognize the differences in breast lesions and histologic features of breast cancers
- Identify which breast lesions require a surgical excision
- Identify the histologic feature commonly associated with triple negative breast cancers
- Identify the genes that underlie the molecular classification of breast cancer
Continuing Medical Education and Continuing Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 29.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit. Physicians can earn a maximum of 23.75 SAM credit hours.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships: Jason L. Hornick, M.D., Ph.D., Consultant, Eli Lily; Consultant, Epizyme
The following faculty reported no relevant financial relationships: Adam Bagg, M.D., Rhonda K. Yantiss, M.D., Jonathan Epstein, M.D., William Faquin, M.D., Ph.D., Kirk D. Jones, M.D., David S. Klimstra, M.D., Glenn McCluggage, FRCPath, Stuart J. Schnitt, M.D.
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.
To earn CME and SAM credit, all learners must complete the evaluation. Your certificate will be available to view and print by clicking here.
Buy the entire 2018 Diagnostic Pathology Update and get a great discount!
Not A Member? Click Here